Porvair Sciences launches first Drosophila ChIP kits
Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.
Porvair Sciences has introduced the first commercial ChIP kit range dedicated to Drosophila (fruit fly). Benefiting from proprietary bead-free ChIP technology, these new kits deliver high-quality ChIP-ready chromatin from as little as 5 Drosophila specimens and from a range of Drosophila tissues.
The fruit fly (Drosophila) is a very widely used model organism for genetic and epigenetic research. However, until now, researchers have had few research protocols at their disposal.
With this new development, Porvair Sciences now offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP. Incorporating correctly orientated capture proteins throughout the inert filter-based ChIP technology, the new Drosophila kits offer outstanding sensitivity which is especially important for detection of binding of low abundant targets. Coupling these advantages with the well-documented benefits of bead-free ChIP assay technology provides Drosophila researchers with an easy, sensitive workflow that can be completed in less than 5 hours.
The new Chromatrap range includes Drosophila UniqSeq, ChIP-Seq, Antibodies and Primer Sets.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.